Kalaris Therapeutics, Inc. (KLRS) Form 10-K Annual Reports
Kalaris Therapeutics, Inc. (KLRS) is a publicly traded company on the Nasdaq, categorized under SIC 2836 (Biological Products, (No Diagnostic Substances)). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: KLRS
CIK: 1754068
Exchange: Nasdaq
SIC 2836: Biological Products, (No Diagnostic Substances)
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
Deloitte & Touche LLP
Auditor SinceSince 12/31/2019 12:00:00 AM
Lead Engagement PartnerJonathan Margate
Audit LocationSan Francisco, California, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 4 | 2026-08-28 | 2026-08-27 | 4 | 0001193125-26-374352 | View SEC Doc Filr Page |
| 10-Q | 2026-08-11 | 2026-06-30 | 10-Q | 0001193125-26-344532 | View SEC Doc Filr Page |
| 8-K | 2026-08-11 | 2026-08-11 | 8-K | 0001193125-26-343477 | View SEC Doc Filr Page |
| 4 | 2026-08-03 | 2026-08-01 | 4 | 0001193125-26-330530 | View SEC Doc Filr Page |
| 3 | 2026-08-03 | 2026-08-01 | 3 | 0001193125-26-330516 | View SEC Doc Filr Page |
| 3 | 2026-07-27 | 2026-07-27 | 3 | 0001193125-26-318054 | View SEC Doc Filr Page |
| 4 | 2026-07-20 | 2026-07-20 | 4 | 0001193125-26-309047 | View SEC Doc Filr Page |
| 3 | 2026-07-20 | 2026-07-20 | 3 | 0001193125-26-309027 | View SEC Doc Filr Page |
| 8-K | 2026-07-20 | 2026-07-14 | 8-K | 0001193125-26-308382 | View SEC Doc Filr Page |
| 8-K | 2026-07-17 | 2026-07-17 | 8-K | 0001193125-26-306737 | View SEC Doc Filr Page |
| 8-K | 2026-07-06 | 2026-07-03 | 8-K | 0001193125-26-296190 | View SEC Doc Filr Page |
| 4 | 2026-06-04 | 2026-06-03 | 4 | 0001193125-26-257564 | View SEC Doc Filr Page |
| 4 | 2026-06-04 | 2026-06-03 | 4 | 0001193125-26-257556 | View SEC Doc Filr Page |
| 4 | 2026-06-04 | 2026-06-03 | 4 | 0001193125-26-257494 | View SEC Doc Filr Page |
| 4 | 2026-06-04 | 2026-06-03 | 4 | 0001193125-26-257471 | View SEC Doc Filr Page |
| 4 | 2026-06-04 | 2026-06-03 | 4 | 0001193125-26-257465 | View SEC Doc Filr Page |
| 4 | 2026-06-04 | 2026-06-03 | 4 | 0001193125-26-257462 | View SEC Doc Filr Page |
| 4 | 2026-06-04 | 2026-06-03 | 4 | 0001193125-26-257445 | View SEC Doc Filr Page |
| 8-K | 2026-06-04 | 2026-06-03 | 8-K | 0001193125-26-257388 | View SEC Doc Filr Page |
| SCHEDULE 13D/A | 2026-05-22 | — | SCHEDULE 13D/A Filing | 0001699737-26-000012 | View SEC Doc Filr Page |
| 4 | 2026-05-22 | 2026-05-20 | 4 Filing | 0001231919-26-000532 | View SEC Doc Filr Page |
| 10-Q | 2026-05-12 | 2026-03-31 | 10-Q | 0001193125-26-219328 | View SEC Doc Filr Page |
| 8-K | 2026-05-12 | 2026-05-12 | 8-K | 0001193125-26-218240 | View SEC Doc Filr Page |
| ARS | 2026-04-24 | 2025-12-31 | ARS | 0001193125-26-177387 | View SEC Doc Filr Page |
| DEFA14A | 2026-04-24 | — | DEFA14A | 0001193125-26-177383 | View SEC Doc Filr Page |